A Leading Producer of Monoclonal Antibodies
LEBANON,
N.H., Aug. 12, 2024 /PRNewswire/ -- Bio X Cell,
LLC ("BXC" or the "Company"), a leading producer of monoclonal
antibodies for pre-clinical in vivo research applications,
is pleased to announce the appointment of Christopher Conway as Chief Executive
Officer.
Mr. Conway has extensive experience in both small molecule and
Biologics drug discovery, most recently as President of Research
and Development (R&D) at Curia. Chris joined Curia (formerly
AMRI) in 2008 from Johnson & Johnson and progressed through a
series of commercial leadership roles. In 2015 he was promoted to
Senior Vice President and Drug Discovery and Development Business
Unit Head. He led that business through a period of significant
organic and inorganic growth culminating in his promotion to
President of the R&D business unit in 2019 and P&L
leadership of twenty sites globally.
"As my successor, Chris not only brings strong business and
industry credentials, but an understanding and respect for Bio X
Cell's culture and mission to advance scientific discovery and
innovation by providing the highest quality products and
exceptional customer service," said the Company's founder,
Klaus Lubbe. Dr. Lubbe sold a
majority stake in BXC to Windjammer Capital Investors
("Windjammer") in November 2023 and
remains involved, particularly with respect to new product
development, as a board member and minority shareholder.
"During his tenure at AMRI/Curia, Chris held diverse leadership
roles and helped the business continue to grow as the company
evolved from founder-led to private equity ownership," said
Craig Majernik, Managing Director at
Windjammer. "That experience, combined with his proven leadership
skillset, commercial expertise and reach across the drug
development industry, make him uniquely qualified to lead BXC
through the next phase of growth and business expansion."
"Bio X Cell's tremendous brand reputation throughout the global
research community, especially within academia and government, is a
testament to the care and attention Klaus and team have brought to
the business since its founding in 1997," said Mr. Conway. "The
opportunity to build on that strong foundation, continue to expand
upon Bio X Cell's high quality, extensive product offering, and
extend its reach within the commercial sector, both organically and
through strategic acquisitions, are what attracted me to the CEO
role."
About Bio X Cell
Bio X Cell is a leading producer of
monoclonal antibodies (mAbs) primarily for use in preclinical in
vivo research applications. The Company's 400+ functional grade
antibodies are used by 1,500+ academic, government and commercial
customers in a wide range of research areas including cancer,
immunology, and neuroscience, reflected in more than 20,000
research publication citations. BXC supplies research use only mAbs
to customers in over fifty countries throughout the Americas,
Europe, and Asia.
Media Contact:
Connor
Halverson
That's Nice LLC, on behalf of Bio X Cell
Tel: +1 212 366 4455
Email: connor@thatsnice.com
To learn more visit https://bioxcell.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-x-cell-announces-ceo-appointment-302219367.html
SOURCE Bio X Cell